Results 261 to 270 of about 56,186 (320)

First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population. [PDF]

J Manag Care Spec Pharm
Sun L, Veenstra DL, Brufsky A, Pluard T, Sandin R, Stergiopoulos S, Liu X, Williams T, Sullivan SD.   +8 more
europepmc   +1 more source

Key therapeutic advances in aromatase inhibitors

Sanjana Bisht, Shashank Kumar, Lajya Devi Goel, Suresh Thareja   +3 more
openalex   +2 more sources

Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trial. [PDF]

PLoS One
Henry NL, Kidwell KM, Kozar S, Snyder S, Zick SM.   +4 more
europepmc   +1 more source

Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. [PDF]

ESMO Open
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A.   +9 more
europepmc   +1 more source

Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy. [PDF]

Breast Cancer Res
Taranto P, de Brito Sales D, Maluf FC, Guendelmann RAK, de Melo Pompei L, Leal A, Buzaid AC, Schvartsman G.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aromatase Inhibitors

Current Medical Research and Opinion, 2001
The new non-steroidal and steroidal aromatase inhibitors are at least as effective as megestrol acetate (MA) as second-line hormonal agents in postmenopausal women with breast cancer. However, they are superior to MA in terms of tolerability and adverse effects.
G H, Cunnick, K, Mokbel
openaire   +4 more sources

Aromatase and aromatase inhibitors

Breast Cancer, 2001
Aromatase inhibition provides both paracrine/intracrine and endocrine treatment. Recent accumulated data clarified that 3rd generation aromatase inhibitors potently suppress intratumoral estrogen synthesis particularly in postmenopausal patients. In the 2nd-line treatment for metastatic breast cancer patients, aromatase inhibitors achieved results ...
M, Toi, H, Bando, S, Saji
openaire   +2 more sources

Novel aromatase inhibitors

The Journal of Steroid Biochemistry and Molecular Biology, 1990
Aminoglutethimide (AG), an inhibitor of the aromatase enzyme, inhibits the biosynthesis of estrogens and displays well-documented anti-tumor efficacy in breast-cancer. However, this efficacy is accompanied by a relative lack of specificity in inhibiting aromatase and moderate tolerability.
A S, Bhatnagar, A, Häusler, K, Schieweck, L J, Browne, R, Bowman, R E, Steele   +5 more
openaire   +2 more sources